Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 9/20 | 0.39 |
| ▸ | JAK1 | P23458 | 9/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127075 | 0.85 | XDH (0.42) | XDHSLC22A12SYK | |
| SCHEMBL10127182 | 0.84 | XDH (0.42) | XDHJAK2JAK1SLC22A12SYK | |
| SCHEMBL282805 | 0.82 | NTRK1 (0.42) | XDHSYK | |
| SCHEMBL10127253 | 0.81 | XDH (0.42) | XDHSLC22A12KITFLT3SYK | |
| SCHEMBL10127028 | 0.81 | SYK (0.41) | XDHJAK2JAK1SYK | |
| SCHEMBL10127150 | 0.80 | XDH (0.46) | XDH | |
| SCHEMBL10127107 | 0.80 | PDE4B (0.43) | XDHJAK2SYK | |
| SCHEMBL10127122 | 0.79 | ATF1 (0.39) | XDHSLC22A12SYK | |
| SCHEMBL10127260 | 0.78 | PNP (0.41) | XDHJAK2JAK1CDK5CDK5R1 | |
| SCHEMBL10156696 | 0.78 | LTA4H (0.41) | XDHSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010128659-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | XDH 3761/4885JAK2 1536/4885JAK1 2743/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | XDH 3761/4885JAK2 1536/4885JAK1 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.